Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Stephen A Strickland, MD MSCI, Nikolai A. Podoltsev, MD PhD, Sanjay R Mohan, MD MSCI, Amer M. Zeidan, MBBS, MHS, Merrida A Childress, PhD, Gregory D Ayers, MS, Michael T Byrne, DO, Steven D. Gore, MD, Robert K. Stuart, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 180.

https://doi.org/10.1182/blood-2019-131520

Published: 2019

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2019) 134 (Supplement_1): 2997.

https://doi.org/10.1182/blood-2019-124136

Published: 2019

Journal Articles

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Michael T Byrne, DO, Nathalie Danielson, MSN, Adrianne Rasche, MSN, Rachel Hammers, MSN, Kathryn A Culos, PharmD, Katie S Gatwood, PharmD, Houston Wyatt, PharmD, Kristin Fogo, BSN, Bhagirathbhai Dholaria, MBBS, Brian G Engelhardt, MD, Paul Brent Ferrell, Jr., MD, Madan Jagasia, MBBS, MS, MMHC, Adetola A. Kassim, MDMS, Sanjay R Mohan, MD MSCI, Bipin N. Savani, MD, Stephen A. Strickland, MD, Salyka M. Sengsayadeth, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2643.

https://doi.org/10.1182/blood-2019-129146

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Richard Thomas T. Maziarz, MD, Mrinal M. Patnaik, MDMBBS, Bart L Scott, MD, Sanjay R. Mohan, MD MSCI, Abhinav Deol, MD, Scott D. Rowley, MD, Dennis Kim, MD, Kelly Haines, Gaetano J Bonifacio, MD, Patrice Rine, Das Purkayastha, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 662.

https://doi.org/10.1182/blood-2018-99-113582

Published: 2018

Journal Articles

Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia (VITAL) Patients Eligible for Intensive Chemotherapy: A Planned Interim Analysis

Stephen A. Strickland, MD MSCI, Nikolai A. Podoltsev, MD PhD, Sanjay R. Mohan, MD MSCI, Amer M. Zeidan, MD, Gregory D. Ayers, MS, Molly Olson, MS, Steven D. Gore, MD, Robert K. Stuart, MD, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 2630.

https://doi.org/10.1182/blood.V130.Suppl_1.2630.2630

Published: 2017

Journal Articles

Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat

Blood (2016) 128 (22): 1166.

https://doi.org/10.1182/blood.V128.22.1166.1166

Published: 2016

Journal Articles

Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Tamara K Moyo, MD PhD, Andrew Sochacki, MD, Gregory D Ayers, MS, Michael T. Byrne, DO, Stephen A. Strickland, Sanjay R. Mohan, MD, Jill Harrison, Lynne D Berry, Channing V Dudley, Rachel Severs, Laura Dugger, Hari P. Miskin, MS, Amy Cavers, Peter Sportelli, Laura C Michaelis, MD, Ruben A. Mesa, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 1125.

https://doi.org/10.1182/blood.V128.22.1125.1125

Published: 2016

Journal Articles

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3 -Itd-Mutated Acute Myeloid Leukemia (AML)

Richard T. Maziarz, MD, Mrinal M Patnaik, MBBS, Bart L. Scott, MD, Sanjay R. Mohan, MD, Abhinav Deol, MD, Scott D. Rowley, MD FACP, Dennis Dong Hwan Kim, MD PhD, Kelly Haines, BS, Gaetano Bonifacio, MD, Patrice Rine, Hugo F. Fernandez, MD

Blood (2016) 128 (22): 2248.

https://doi.org/10.1182/blood.V128.22.2248.2248

Published: 2016

Journal Articles

SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 901.

https://doi.org/10.1182/blood.V128.22.901.901

Published: 2016

Journal Articles

Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status

Caroline R Cantilena, BA, Xin Zhao, MD PhD, Sachiko Kajigaya, PhD, Neil Dunavin, MD, Xin Tian, PhD, Stephen A. Strickland, MD, Bipin N. Savani, MD, Sanjay R. Mohan, MD, Katayoun Rezvani, MDPhD, Xingmin Feng, PhD, Danielle M. Townsley, MD, Minoo Battiwalla, MDMS, Sawa Ito, MD, Austin John Barrett, MDFRCP,FRCPath

Blood (2015) 126 (23): 1267.

https://doi.org/10.1182/blood.V126.23.1267.1267

Published: 2015

Journal Articles

Mutational Burden in Acute Myeloid Leukemia Is Largely Age Dependent

Aaron C. Shaver, MD PhD, Adam C. Seegmiller, MD PhD, Stephen A. Strickland, MD, Robert D. Daber, PhD, Sanjay R. Mohan, MD, Paul Brent Ferrell, Jr., MD, Cindy Vnencak-Jones, PhD, David R. Head, MD, Annette S. Kim, MD PhD, Mary M. Zutter, MD, Michael R. Savona, MD

Blood (2015) 126 (23): 2605.

https://doi.org/10.1182/blood.V126.23.2605.2605

Published: 2015

Journal Articles

Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML.

Moshe Ornstein, MD, MA, Sudipto Mukherjee, MD PhD, Sanjay R. Mohan, MD, Paul Elson, ScD, Ramon V. Tiu, MD, Yogenthiran Saunthararajah, M.D., Leslie Farhat, Cassandra Kendeigh, Anjali Advani, MD, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, MD, PhD, Mikkael A. Sekeres, MD, MS

Blood (2012) 120 (21): 2589.

https://doi.org/10.1182/blood.V120.21.2589.2589

Published: 2012

Journal Articles

New TET2 , ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders

Fabiola Traina, MD, PhD, Ania Jankowska, MSC, Hideki Makishima, MD, PhD, Fred H. Hsieh, MD, Yingchun Han, PhD, Christine O'Keefe, PhD, Yuka Sugimoto, MD, PhD, Sanjay R. Mohan, MD, Hadrian Szpurka, PhD, Courtney Prince, Kathryn Guinta, MSC, Mikkael A. Sekeres, MD, MS, Matt Kalaycio, MD, Alan E. Lichtin, MD, Anjali S. Advani, MD, Edward Copelan, MD, Ronald Sobecks, MD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Ramon V. Tiu, MD

Blood (2010) 116 (21): 3076.

https://doi.org/10.1182/blood.V116.21.3076.3076

Published: 2010

Journal Articles

Various Abnormalities at Chromosome 7 Carry Distinct Biologic and Prognostic Implications In Myelodysplastic/Myeloproliferative Syndromes and Related Marrow Failures

Aaron D Viny, MD, MS, Bartlomiej Przychodzen, Christine L. O'Keefe, PhD, Hideki Makishima, MD, PhD, Yuka Sugimoto, MD, PhD, Sanjay R. Mohan, MD, Marcin W. Wlodarski, M.D., Seiji Kojima, MD, PhD, Mikkael A. Sekeres, MD, MS, Jaroslaw P Maciejewski, MD, PhD, FACP

Blood (2010) 116 (21): 2744.

https://doi.org/10.1182/blood.V116.21.2744.2744

Published: 2010

Journal Articles

A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML

Sanjay R. Mohan, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Bindu Tejura, Harry P Erba, DM, PhD, Richard M Stone, M.D., Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 2139.

https://doi.org/10.1182/blood.V116.21.2139.2139

Published: 2010

Journal Articles

Efficacy of Rabbit Anti-Thymocyte Globulin (ATG) Compared to Horse ATG In Severe Aplastic Anemia

Manuel Afable, II, Mohammed Shaik, MD, Yuka Sugimoto, MD, PhD, Michael Clemente, Ramon V. Tiu, MD, Sanjay R. Mohan, MD, Nelli Bejanyan, Paul Elson, Matt Kalaycio, MD, Anjali Advani, MD, Ronald Sobecks, MD, Alan E. Lichtin, MD, Mikkael A. Sekeres, MD, MS, Jaroslaw Maciejewski

Blood (2010) 116 (21): 2236.

https://doi.org/10.1182/blood.V116.21.2236.2236

Published: 2010

Journal Articles

Analysis of Readmission After Autologous HCT: Predictive Factors and Clinical Consequences

Sanjay R. Mohan, MD, Lisa Rybicki, MS, Stephen D. Smith, MD, Robert Dean, MD, Brad Pohlman, MD, John William Sweetenham, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Steven Andresen, DO, Edward A. Copelan, MD, Brian J. Bolwell, MD

Blood (2010) 116 (21): 932.

https://doi.org/10.1182/blood.V116.21.932.932

Published: 2010

Journal Articles

Duration of Antecedent Complete Blood Cell Count (CBC) Abnormalities Predicts Response and Survival Rates In De Novo and Secondary AML.

Sanjay R. Mohan, MD, Paul Elson, Ramon V. Tiu, MD, Anjali Advani, MD, Yogen Saunthararajah, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Edward Copelan, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 1040.

https://doi.org/10.1182/blood.V116.21.1040.1040

Published: 2010

Journal Articles

Chimerism Analysis Is Predictive of Relapse-Free Survival After Allogeneic Transplantation for MDS

Sanjay R. Mohan, MD, Lisa Rybicki, MS, Matt Kalaycio, MD, Ronald Sobecks, MD, Brian J. Bolwell, MD, Edward A. Copelan, MD

Blood (2010) 116 (21): 1332.

https://doi.org/10.1182/blood.V116.21.1332.1332

Published: 2010

NARROW

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia (VITAL) Patients Eligible for Intensive Chemotherapy: A Planned Interim Analysis

Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3 -Itd-Mutated Acute Myeloid Leukemia (AML)

SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status

Mutational Burden in Acute Myeloid Leukemia Is Largely Age Dependent

Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML.

New TET2 , ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders

Various Abnormalities at Chromosome 7 Carry Distinct Biologic and Prognostic Implications In Myelodysplastic/Myeloproliferative Syndromes and Related Marrow Failures

A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML

Efficacy of Rabbit Anti-Thymocyte Globulin (ATG) Compared to Horse ATG In Severe Aplastic Anemia

Analysis of Readmission After Autologous HCT: Predictive Factors and Clinical Consequences

Duration of Antecedent Complete Blood Cell Count (CBC) Abnormalities Predicts Response and Survival Rates In De Novo and Secondary AML.

Chimerism Analysis Is Predictive of Relapse-Free Survival After Allogeneic Transplantation for MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only